Kalshi launches prediction markets for clinical trial results and FDA approvals
Kalshi, a major prediction market exchange, announced it will begin offering markets that let participants bet on the outcomes of clinical trials and on whether drugs will receive FDA approval.
The company is launching the service in collaboration with AppliedXL, a technology firm that tracks and forecasts trial results. The initial offering will include a limited set of markets selected with AppliedXL’s input.
By bringing prediction markets to biopharma, Kalshi hopes to give companies and investors a new tool for assessing risk and potential reward, echoing the use of similar markets in sports and politics.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvals”
read at STAT ↗
comments(0)
5-min edit window · permanent after that